Patents Examined by Amelia Nicole Dickens
  • Patent number: 11970690
    Abstract: The present disclosure is directed to a method for cultivating a Bordetella species, comprising: cultivating a Bordetella species under aerobic conditions in a liquid culture medium; and maintaining a pH of the liquid culture medium by using a strong acid, such as nitric acid, or using a first and second acid, wherein the first acid is an inorganic acid that dissociates essentially completely in water, such as nitric acid, hydrochloric acid or sulfuric acid, and wherein the second acid is an inorganic acid having an acid dissociation constant (pKa) of greater than 1, such as phosphoric acid. Methods for increasing the yield of Bordetella fimbrial agglutinogen 2 and fimbrial agglutinogen 3 (FIM2/3) in a supernatant fraction from a Bordetella culture are also provided.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: April 30, 2024
    Assignee: SANOFI PASTEUR INC.
    Inventors: Patrick Farrell, Bo Zhi Sun, Fabien Barbirato, Javier de Jesus Menendez Diaz, Andrew Chiappetta
  • Patent number: 11957723
    Abstract: Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: April 16, 2024
    Assignee: MarvelBiome, Inc.
    Inventors: Jothi Amaranath Govindan, Elamparithi Jayamani, Priti H. Chatter, Mukesh Chatter
  • Patent number: 11912743
    Abstract: Polypeptides comprising a fragment of a teleost invariant chain fused to one or more antigens can enhance T cell response. Alternatively a teleost invariant chain fused to one or more antigens or antigenic fragments thereof can be used. A polynucleotide encoding such polypeptides, vectors comprising such polynucleotides, collection of vectors comprising such polynucleotides are also disclosed. The use of such polypeptides, polynucleotides, vectors for treating or preventing diseases, in particular tumor diseases are also encompassed by the present invention. The teleost invariant chain polypeptides or fragments thereof act as “T cell enhancer” converting non-immunogenic antigenic sequences into immunogenic T cell antigens.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 27, 2024
    Assignee: NOUSCOM AG
    Inventors: Alfredo Nicosia, Elisa Scarselli, Armin Lahm, Antonella Folgori
  • Patent number: 11897923
    Abstract: The present invention relates to a coding gene of the SOSEKI protein SOK2 and an application thereof, wherein through molecular regulation of the SOSEKI protein SOK2, the flowering time of Panicum virgatum is delayed, biomass is increased, lignin content in the cell wall of Panicum virgatum is reduced and the fermentable sugar yield is boosted.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: February 13, 2024
    Inventors: Chunxiang Fu, Yamei Wang, Wenwen Liu, Zhenying Wu, Shiqie Bai, Chuan'en Zhou, Ruijuan Yang, Shanshan Jiang, Mengqi Wang
  • Patent number: 11883478
    Abstract: The application discloses method of immunising against Neisseria meningitidis infection comprising the steps of a) immunising a human patient at a first age of between 0 and 11 months with a bacterial saccharide conjugate vaccine comprising at least one, two or three bacterial saccharide(s) separately conjugated to a carrier protein to form at least one, two or three bacterial saccharide conjugate(s); and b) immunising the human patient at a second age of between 12 and 24 months with a Neisseria meningitidis conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of N. meningitidis serogroup A capsular saccharide (MenA), N. meningitidis serogroup C capsular saccharide (MenC), N. meningitidis serogroup W135 capsular saccharide (MenW135), and N.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 30, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Yaela Baine, Jacqueline Miller
  • Patent number: 11872267
    Abstract: Disclosed herein are compositions and methods for treating uterine fibroids in vivo, and methods of reducing symptoms associated with uterine fibroids, including pain, bleeding and infertility. The disclosed compositions comprise collagenase in an amount effective to cause shrinkage and/or reduce stiffness of uterine fibroids.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: January 16, 2024
    Assignees: The Johns Hopkins University, Duke University, BioSpecifics Technologies LLC
    Inventors: James H. Segars, Phyllis Carolyn Leppert, Thomas L. Wegman, Jean-Marie Soma
  • Patent number: 11844829
    Abstract: An isolated Streptococcus pneumoniae membrane vesicle microparticle (MP), wherein said MP comprises: the protein Ply at the level of ?0.070 ?g/?g total protein in the MP; and/or the protein LytA at the level of ?0.070 ?g/?g total protein in the MP; and/or the protein PspC at the level of ?0.130 ?g/?g total protein in the MP; and/or the protein RrgB at the level of ?0.020 ?g/?g total protein in the MP. Compositions comprising such MPs. Uses thereof in particular in immunization, as well as methods of manufacture thereof.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 19, 2023
    Assignee: ZalVac AB
    Inventors: Birgitta Henriques Normark, Mario Codemo, Federico Iovino, Sandra Muschiol, Staffan Normark, Sun Nyunt Wai
  • Patent number: 11845940
    Abstract: The present invention provides for a genetically modified fungal host cell capable of producing prespatane and/or epi-isozizaene comprising prespatane synthase (PPS) and/or epi-isozizaene synthase (EIZS).
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: December 19, 2023
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC
    Inventors: Gina Marie Geiselman, James Kirby, Taek Soon Lee, John M. Gladden, Blake A. Simmons
  • Patent number: 11786554
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: October 17, 2023
    Assignee: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
  • Patent number: 11782064
    Abstract: The invention, in some aspects, relates to the preparation and use of signaling reporter islands (SiRIs) in single cells. Compositions of the invention that produce SiRIs can be delivered to a cell resulting in the presence of one or more SiRIs in the cell. Methods of the invention include detecting signals generated by elements in the SiRIs in a cell and use of the detected signals to determine and analyze simultaneous physiological processes within the cell, or cells.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: October 10, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Changyang Linghu, Shannon L. Johnson, Edward Stuart Boyden
  • Patent number: 11781106
    Abstract: A method for transfecting microorganisms comprises inoculating a growth media consisting of at least one of sterile LB media and tryptic soy broth with microorganism cells (cells) consisting of at least one of E.coli (DH5?), C. lytica, or B. subtilus, Pichia pastoris; growing the cells at between 28-40° C. to achieve a desired cell density; harvesting the cells; adding a protein ionic liquid consisting of at least one of green fluorescent protein (GFP), ferritin, rabbit IgG antibodies, and photosystem II from spinach ionic liquid to the cells; suspending the cells in the protein ionic liquid; freezing the suspended cells between ?20 to ?212° C.; and removing at least 99% of water from the frozen suspended cells to make a cell powder. The cell powder may be reconstituted in Tris HCl buffer and mixed to obtain uniform cell suspension; and centrifuged to obtain cell pellet.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: October 10, 2023
    Assignee: United States of America as represented by the Secretary of the Air Force
    Inventors: Joseph M Slocik, Rajesh R. Naik, Patrick B Dennis
  • Patent number: 11740236
    Abstract: The present disclosure relates to proteins comprising a target-binding domain for detection of a target of interest, methods, compositions and kits thereof.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: August 29, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Hadley Sikes Johnson, Eric Alexander Miller, Ki-Joo Sung
  • Patent number: 11732243
    Abstract: A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria; wherein the bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 22, 2023
    Assignee: PHICO THERAPEUTICS LTD
    Inventors: Heather Fairhead, Adam Wilkinson
  • Patent number: 11723935
    Abstract: The application relates to methods based on modulating mammalian intestinal and/or pancreatic microbiota and related probiotic, prebiotic, and anti-bacterial compositions. Specifically, the application relates to the use of microbiome for prevention, treatment and diagnosis of pancreatic cancers or tumors, such as pancreatic ductal adenocarcinoma.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: August 15, 2023
    Assignee: NEW YORK UNIVERSITY
    Inventors: George Miller, Deepak Saxena, Smruti Pushalkar
  • Patent number: 11719706
    Abstract: Disclosed is a method for measuring a biomarker in a biological sample of the IPAF patient, wherein the biomarker comprises at least one selected from the group consisting of CXCL9 and CXCL10, and a measurement result of the biomarker is used as an index for determining treatment responsiveness to anti-inflammatory therapy.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: August 8, 2023
    Assignees: SAPPORO MEDICAL UNIVERSITY, SYSMEX CORPORATION
    Inventors: Masami Kameda, Mitsuo Otsuka, Takehiro Hasegawa
  • Patent number: 11662353
    Abstract: A method for assessing an effect of hypoxia on a tissue includes providing a sample of the tissue in a hermetically sealed container, determining a first amount of a reaction substrate (e.g., protocatechuic acid) to be introduced into the sealed container and determining a second amount of a reaction enzyme (e.g., protocatechuate dioxygenase) to be introduced into the sealed container. The method further includes introducing the reaction substrate and the reaction enzyme into the sealed container. At least one of the first amount of the reaction substrate and the second amount of the reaction enzyme is selected to induce at least one of a predetermined amount of hypoxia less than anoxia and a predetermined rate of hypoxia in the tissue during a reaction between the reaction substrate and the reaction enzyme. Values of properties of the tissue can be measured before and after the reaction to assess effects of hypoxia.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: May 30, 2023
    Assignee: Functional Fluidics Inc.
    Inventors: Michael Tarasev, Lucas Gelmini
  • Patent number: 11643455
    Abstract: Provided are high affinity Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: May 9, 2023
    Assignee: Albert Einstein College of Medicine
    Inventors: Jacqueline M. Achkar, Jonathan Lai, Elise Ishida, Daniel Hofmann, Tingting Chen
  • Patent number: 11643465
    Abstract: The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: May 9, 2023
    Assignee: WuXi Biologics Ireland Limited
    Inventors: Yong Zheng, Jing Li, Zhisheng Chen
  • Patent number: 11583574
    Abstract: An oral product comprising nano-sized, heat tolerable, shelf stable peptides and enzymes. Once the peptides and enzymes are inside the body of a user, they dimerize the nucleic acids of viruses, bacteria and fungi. Thus, the peptides and enzymes are capable of inactivating the genome of pathogens, including without limitation, SARS-CoV-2 and Influenza A/CA/04/2009 (H1N1) virus.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: February 21, 2023
    Inventor: Mitchell Lynn Tate
  • Patent number: 11541082
    Abstract: The invention provides a microbial composition in the form of a powder for oral administration comprising or consisting of: (i) micro-organism, preferably probiotic bacteria; (ii) sugar alcohol, such as Erythritol and Xylitol; (iii) moisture absorbent fibre, such as inulin; (iv) a flow agent, such a silicon dioxide optionally; (v) a flavorant; and/or optionally (vi) a bulking agent, such as maltodextrin. The compositions display good storage stability, fast-melt and sensory properties. They are preferably packaged in a single dose in a sealed stick pack aluminium container.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: January 3, 2023
    Assignee: Probi AB
    Inventors: Malin Björklund, Jenny Rudolfsson